Oct 24 (Reuters) - Celsion Corp ::CELSION ANNOUNCES PROGRESSION-FREE SURVIVAL DATA FROM GEN-1 PHASE I IMMUNO-ONCOLOGY STUDY OF PATIENTS WITH STAGE III/IV OVARIAN CANCER.CELSION CORP - STUDY DEMONSTRATED THAT GEN-1 IS WELL TOLERATED.CELSION CORP - ALL PATIENTS TREATED AT HIGHEST DOSE COHORT ACHIEVED COMPLETE SURGICAL RESECTION AFTER INTERVAL DEBULKING SURGERY.CELSION CORP - FIRST DATA ANALYSIS FROM PHASE I/II OVATION 2 STUDY IS EXPECTED IN FIRST HALF OF 2019.
Full Article
Sept 7 (Reuters) - Celsion Corp ::CELSION CORP FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING.
Full Article
Sept 4 (Reuters) - Celsion Corp ::PRESS RELEASE - CELSION STRENGTHENS ITS BALANCE SHEET WITH THE APPROVAL OF ITS APPLICATION TO SELL NET OPERATING LOSSES FOR UP TO $10 MILLION IN NON-DILUTIVE FUNDING.CELSION - CO ANTICIPATES TO TRANSFER CREDIT & RECEIVE UPTO $10 MILLION NET CASH PROCEEDS PRIOR TO 2018-END.
Full Article
June 28 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES STRATEGIC LOAN FACILITY.CELSION CORP - ON JUNE 27, ENTERED INTO A $10 MILLION LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION.CELSION CORP - WILL USE FUNDING PROVIDED UNDER AGREEMENT FOR WORKING CAPITAL AND ADVANCEMENT OF ITS PRODUCT PIPELINE.
Full Article
Jan 4 (Reuters) - Celsion Corp ::CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER.CELSION CORP - EXPECTS TO INITIATE ENROLLMENT OF PHASE I PORTION OF OVATION II STUDY IN FIRST HALF OF 2018.CELSION CORP - COMPANY EXPECTS TO HAVE 25% OF OVATION II STUDY ENROLLED BY END OF 2018.
Full Article
Nov 14 (Reuters) - Celsion Corp :Celsion Corporation reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.70.
Full Article
Oct 27 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK.PRICING OF OFFERING OF 2.64 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 1.32 MILLION SHARES OF COMMON STOCK AT $2.50/SHARE, RELATED WARRANTS.
Full Article
Aug 15 (Reuters) - Celsion Corp :Celsion corporation reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.79.Celsion corp - expects to complete enrollment of optima study by mid - 2018..
Full Article
June 22 (Reuters) - Celsion Corp ::Celsion Corporation announces cancellation of registered direct offering.Company noted it did not possess ability to register a sufficient number of shares pursuant to form S-3 until July 1, 2017.Company has entered into an agreement with each of investors to terminate offering.Cancelled registered direct offering of common stock announced Monday, June 19.
Full Article
Earnings vs. 
Estimates